|
AU584417B2
(en)
|
1985-04-01 |
1989-05-25 |
Lonza Group Ag |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US5589173A
(en)
|
1986-11-04 |
1996-12-31 |
Genentech, Inc. |
Method and therapeutic compositions for the treatment of myocardial infarction
|
|
US5437864A
(en)
|
1987-03-31 |
1995-08-01 |
The Scripps Research Institute |
Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
|
|
US5223427A
(en)
|
1987-03-31 |
1993-06-29 |
The Scripps Research Institute |
Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
WO1989011297A1
(en)
|
1988-05-27 |
1989-11-30 |
Centocor, Inc. |
Freeze-dried formulation for antibody products
|
|
EP0420937B1
(en)
|
1988-06-21 |
1994-11-09 |
Genentech, Inc. |
Therapeutic compositions for the treatment of myocardial infarction
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5506134A
(en)
|
1990-10-22 |
1996-04-09 |
Corvas International, Inc. |
Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
|
|
JP3149960B2
(ja)
|
1991-01-24 |
2001-03-26 |
財団法人化学及血清療法研究所 |
ヒト組織因子を定量する方法
|
|
US5525497A
(en)
|
1991-11-27 |
1996-06-11 |
Keller; Walter |
Recombinant poly(A) polymerase
|
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
JPH05244988A
(ja)
|
1992-03-04 |
1993-09-24 |
Green Cross Corp:The |
抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
|
|
WO1994005328A1
(en)
|
1992-08-28 |
1994-03-17 |
The Scripps Research Institute |
Inhibition of tumor metastasis via neutralization of tissue factor function
|
|
US5879677A
(en)
|
1992-12-09 |
1999-03-09 |
The Scripps Research Institute |
Method for inhibition of cerebral tissue factor mediated reperfusion damage
|
|
AU702250B2
(en)
|
1994-07-11 |
1999-02-18 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the specific coagulation of vasculature
|
|
PT833911E
(pt)
|
1995-06-07 |
2004-09-30 |
Ortho Mcneil Pharm Inc |
Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
JPH09302000A
(ja)
|
1996-05-16 |
1997-11-25 |
Chemo Sero Therapeut Res Inst |
抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
|
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
|
US20040229282A1
(en)
|
1997-03-10 |
2004-11-18 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US5986065A
(en)
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US7749498B2
(en)
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
EP0999853B1
(en)
|
1997-06-13 |
2003-01-02 |
Genentech, Inc. |
Stabilized antibody formulation
|
|
US6677436B1
(en)
|
1998-04-03 |
2004-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
|
|
JP2001213804A
(ja)
|
2000-01-31 |
2001-08-07 |
Chugai Pharmaceut Co Ltd |
抗組織因子抗体の複合体
|
|
EP1263960A2
(en)
|
2000-03-16 |
2002-12-11 |
Genentech, Inc. |
Anti-tissue factor antibodies with enhanced anticoagulant potency
|
|
WO2002011753A1
(en)
|
2000-08-04 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Protein injection preparations
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
EP1374896A4
(en)
|
2001-03-26 |
2005-04-06 |
Koji Suzuki |
MEANS TO IMPROVE THE FLUID CHARACTERISTICS OF BLOOD
|
|
US6605478B2
(en)
|
2001-03-30 |
2003-08-12 |
Appleid Materials, Inc, |
Kill index analysis for automatic defect classification in semiconductor wafers
|
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
EP1429650B1
(en)
|
2001-08-30 |
2009-06-24 |
Mount Sinai School of Medicine of New York University |
Alternatively spliced circulating tissue factor
|
|
EP1434802A1
(en)
|
2001-10-02 |
2004-07-07 |
Novo Nordisk A/S |
Human tissue factor antibodies
|
|
US20050169927A1
(en)
|
2001-10-02 |
2005-08-04 |
Novo Nordisk A/S |
Human tissue factor antibodies
|
|
TWI338009B
(en)
|
2001-10-29 |
2011-03-01 |
Genentech Inc |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
|
JP2005507008A
(ja)
|
2001-11-02 |
2005-03-10 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
アポトーシスに関連した症状の治療のための、組織因子アゴニストまたは組織因子アンタゴニストの使用
|
|
JP5290489B2
(ja)
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Ｉｇｇ抗体の安定な液体医薬製剤
|
|
CA2476832A1
(en)
|
2002-02-22 |
2003-08-28 |
Prophy Med Ab |
Use of an inhibitor or antagonist against tissue factor
|
|
US20070148171A1
(en)
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
JP4567437B2
(ja)
|
2002-05-01 |
2010-10-20 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
|
|
WO2004004639A2
(en)
|
2002-07-02 |
2004-01-15 |
Smithkline Beecham Corporation |
A novel stable formulation
|
|
AU2003242506A1
(en)
|
2002-07-12 |
2004-02-02 |
Novo Nordisk A/S |
Tf antagonist
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003277832A1
(en)
|
2002-10-31 |
2004-05-25 |
Novo Nordisk A/S |
Humanized tissue factor antibodies
|
|
WO2004041296A2
(en)
|
2002-11-06 |
2004-05-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
|
|
WO2004041302A1
(en)
|
2002-11-06 |
2004-05-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
JP2006516564A
(ja)
|
2003-01-22 |
2006-07-06 |
ノボ ノルディスク アクティーゼルスカブ |
Ｔｆ結合薬剤及びそれらの使用
|
|
RU2358763C2
(ru)
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
US20060034846A1
(en)
|
2003-04-14 |
2006-02-16 |
Mirella Ezban |
Use of TF antagonists
|
|
US7425328B2
(en)
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
|
AU2004251161A1
(en)
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
|
KR20060035608A
(ko)
|
2003-05-30 |
2006-04-26 |
센토코 인코포레이티드 |
항 조직 인자 항체로 종양 성장을 저해하는 방법
|
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
|
AU2004255553B2
(en)
|
2003-06-19 |
2009-08-20 |
Genentech, Inc. |
Compositions and methods for treating coagulation related disorders
|
|
WO2005025623A2
(en)
|
2003-07-28 |
2005-03-24 |
Emory University |
Ef-24-factor vii conjugates
|
|
US20050028649A1
(en)
|
2003-08-06 |
2005-02-10 |
Dan Settanni |
Box wrench with hinged socket
|
|
WO2005020927A2
(en)
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
WO2005079766A2
(en)
|
2004-02-20 |
2005-09-01 |
Novo Nordisk A/S |
Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
|
|
WO2005118646A2
(en)
|
2004-04-26 |
2005-12-15 |
Centocor, Inc. |
Epitope directed selection of antibodies to murine tissue factor
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
WO2006014965A2
(en)
|
2004-07-27 |
2006-02-09 |
Human Genome Sciences, Inc. |
Pharmaceutical formulation and process
|
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
EP1817341A2
(en)
|
2004-11-29 |
2007-08-15 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
|
EP1676574A3
(en)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Methods for promoting survival of transplanted tissues and cells
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
WO2007008600A2
(en)
|
2005-07-07 |
2007-01-18 |
Nellix, Inc. |
Systems and methods for endovascular aneurysm treatment
|
|
CA2615374A1
(en)
|
2005-07-18 |
2007-01-25 |
Ernest Kun Kun |
Treatment of cancer
|
|
CN101237881B
(zh)
|
2005-08-03 |
2015-04-22 |
伊缪诺金公司 |
免疫偶联物剂型
|
|
WO2007019232A2
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
US20090214563A1
(en)
|
2005-10-21 |
2009-08-27 |
Genentech, Inc. |
Treatment for antiphospholipid-syndrome-related pregnancy complications
|
|
BRPI0618338A2
(pt)
|
2005-11-07 |
2011-08-23 |
Scripps Resarch Inst |
uso de inibidor de sinalização de fator tecidual, método para identificar um agente que inibe a sinalização de tf/viia, composições farmacêuticas e kit
|
|
WO2007058935A2
(en)
|
2005-11-14 |
2007-05-24 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
WO2008030260A2
(en)
|
2005-12-22 |
2008-03-13 |
Genentech, Inc. |
Treatment of variola viral infections using a tissue factor inhibitor
|
|
JP2007196364A
(ja)
|
2005-12-28 |
2007-08-09 |
Sumitomo Electric Ind Ltd |
表面被覆切削工具およびその製造方法
|
|
KR20140116546A
(ko)
|
2006-10-27 |
2014-10-02 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
|
AR065271A1
(es)
|
2007-02-09 |
2009-05-27 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos
|
|
US20080311034A1
(en)
|
2007-04-30 |
2008-12-18 |
Anderson Glenn M |
Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
CA2686225A1
(en)
|
2007-06-22 |
2008-12-31 |
Scidose Llc |
Solubilized formulation of docetaxel without tween 80
|
|
CN101969970B
(zh)
|
2007-10-12 |
2014-10-15 |
西雅图基因公司 |
用抗体-药物偶联物联合治疗
|
|
JP4824710B2
(ja)
|
2008-02-08 |
2011-11-30 |
国立清華大学 |
グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法
|
|
AU2009316592B2
(en)
|
2008-11-20 |
2016-01-07 |
Genentech, Inc. |
Therapeutic protein formulations
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
CA3159253A1
(en)
|
2009-01-09 |
2010-07-15 |
Seagen Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
EP3511342B1
(en)
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
CN104998269B
(zh)
|
2010-03-22 |
2019-06-11 |
弗·哈夫曼-拉罗切有限公司 |
对于稳定含有蛋白质的制剂有用的组合物和方法
|
|
JP6055404B2
(ja)
|
2010-06-15 |
2016-12-27 |
ゲンマブ エー／エス |
組織因子に対するヒト抗体薬物結合体
|
|
US20160120976A1
(en)
|
2010-08-18 |
2016-05-05 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
KR102557309B1
(ko)
|
2012-05-15 |
2023-07-20 |
씨젠 인크. |
자가-안정화 링커 접합체
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
MX379066B
(es)
|
2012-09-18 |
2025-03-04 |
Taris Biomedical Llc |
Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
|
|
PL2991683T3
(pl)
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
KR102372245B1
(ko)
*
|
2013-11-21 |
2022-03-08 |
젠맵 에이/에스 |
항체-약물 접합체 동결건조 제제
|
|
EP3074423A1
(en)
|
2013-11-25 |
2016-10-05 |
Oxford BioTherapeutics Ltd |
Antibodies anti matriptase for the treatment of cancer
|
|
WO2015088847A1
(en)
|
2013-12-11 |
2015-06-18 |
Glaxosmithkline Llc |
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
CA2942039A1
(en)
|
2014-02-18 |
2015-08-27 |
Health Research, Inc. |
Combination therapy for hepatocellular carcinoma
|
|
ES2895623T3
(es)
|
2014-05-22 |
2022-02-22 |
Byondis Bv |
Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
CN105330740B
(zh)
|
2014-07-30 |
2018-08-17 |
珠海市丽珠单抗生物技术有限公司 |
抗pd-1抗体及其应用
|
|
CA2955676A1
(en)
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
|
BR112017010788A2
(pt)
|
2014-12-23 |
2017-12-26 |
Genentech Inc |
métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
HUE055109T2
(hu)
*
|
2015-09-11 |
2021-11-29 |
Genmab As |
Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
|
|
PL3368572T3
(pl)
|
2015-10-02 |
2022-09-12 |
Symphogen A/S |
Przeciwciała anty-PD-1 oraz kompozycje
|
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
US10613092B2
(en)
|
2016-04-01 |
2020-04-07 |
Agilent Technologies, Inc. |
Scoring methods for anti-PD therapy eligibility and compositions for performing same
|
|
CN107286242B
(zh)
|
2016-04-01 |
2019-03-22 |
中山康方生物医药有限公司 |
抗pd-1的单克隆抗体
|
|
AU2017266298B2
(en)
|
2016-05-18 |
2024-01-04 |
Boehringer Ingelheim International Gmbh |
Anti PD-1 and anti-LAG3 antibodies for cancer treatment
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
CN106938051B
(zh)
|
2016-08-22 |
2019-10-11 |
复旦大学 |
靶向于组织因子的抗体-药物偶联物
|
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业（苏州）有限公司 |
一种新的pd-1单克隆抗体
|
|
CN107077506A
(zh)
|
2016-12-07 |
2017-08-18 |
深圳市大疆创新科技有限公司 |
无人机的控制方法及无人机
|
|
IL274122B2
(en)
|
2017-11-02 |
2024-09-01 |
Genmab As |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
EP3735271A4
(en)
|
2018-01-04 |
2022-06-15 |
Iconic Therapeutics, Inc. |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
|
|
CN112105388A
(zh)
|
2018-03-07 |
2020-12-18 |
展马博联合股份有限公司 |
抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
JP6833756B2
(ja)
|
2018-04-13 |
2021-02-24 |
日本電信電話株式会社 |
光演算素子と多層ニューラルネットワーク
|
|
WO2019217457A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
AU2019321442A1
(en)
|
2018-08-16 |
2021-02-11 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
KR20220093344A
(ko)
|
2019-11-07 |
2022-07-05 |
도쿄엘렉트론가부시키가이샤 |
기판 처리 장치, 기판 처리 방법 및 기억 매체
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
|
MX2022015375A
(es)
|
2020-06-29 |
2023-01-16 |
Genmab As |
Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
|